A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy

Trial Profile

A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Finerenone (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms ARTS-DN
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 01 Sep 2015 Results published in the JAMA: the Journal of the American Medical Association.
    • 31 Aug 2015 Results published in a Bayer media release.
    • 31 Aug 2015 According to a Bayer media release, data from this study were presented at the World Congress of Nephrology (WCN) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top